Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort
暂无分享,去创建一个
M. Sandhu | N. Wareham | J. Tardif | M. Dubé | K. Khaw | S. Boekholdt | É. Rhéaume | B. Arsenault | M. Sandhu | N. Wareham | Benoit J Arsenault | B. Arsenault
[1] Kathleen F. Kerr,et al. Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.
[2] C. Becker,et al. Lipoprotein (a) is independently correlated with coronary artery calcification. , 2013, European journal of internal medicine.
[3] D. Gurdasani,et al. Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease: The EPIC-Norfolk Prospective Population Study , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[4] F. Raal,et al. Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole , 2012, Circulation.
[5] J. Tardif,et al. Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy , 2012, PloS one.
[6] B. Iung,et al. Degenerative calcific aortic stenosis: a natural history , 2012, Heart.
[7] Tanya M. Teslovich,et al. The Metabochip, a Custom Genotyping Array for Genetic Studies of Metabolic, Cardiovascular, and Anthropometric Traits , 2012, PLoS genetics.
[8] F. Hu,et al. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. , 2012, European heart journal.
[9] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[10] P. Joshi,et al. Abnormal Lipoprotein(a) Levels Predict Coronary Artery Calcification in Southeast Asians but Not in Caucasians: Use of Noninvasive Imaging for Evaluation of an Emerging Risk Factor , 2011, Journal of cardiovascular translational research.
[11] J. Borén,et al. Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.
[12] A. Gotlieb,et al. Common pathogenic features of atherosclerosis and calcific aortic stenosis: role of transforming growth factor-beta. , 2010, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[13] P. Ladenson,et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. , 2010, The New England journal of medicine.
[14] R. Collins,et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.
[15] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[16] Y. Bossé,et al. Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis. , 2008, Journal of the American College of Cardiology.
[17] K. Furie,et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.
[18] J. Després,et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis , 2007, Heart.
[19] A. Yıldırır,et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. , 2007, The Journal of heart valve disease.
[20] T. Thom,et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee : Heart disease and stroke statistical-2006 update : A report from the American Heart Association Statistics Committee and Stroke statistics subcommittee , 2006 .
[21] Jonathan C. Cohen,et al. Lipoprotein(a) and Apolipoprotein(a) Isoforms: No Association With Coronary Artery Calcification in The Dallas Heart Study , 2005, Circulation.
[22] P. Saikku,et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. , 2003, European heart journal.
[23] O. Klezovitch,et al. Stimulation of Interleukin-8 Production in Human THP-1 Macrophages by Apolipoprotein(a) , 2001, The Journal of Biological Chemistry.
[24] M. Schemper,et al. Predictors of outcome in severe, asymptomatic aortic stenosis. , 2000, The New England journal of medicine.
[25] N. Day,et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.
[26] Catherine M. Otto,et al. Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .
[27] Bonnie K. Lind,et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. , 1997, Journal of the American College of Cardiology.
[28] P. Weissberg,et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.
[29] E. Boerwinkle,et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. , 1992, The Journal of clinical investigation.
[30] W. Edwards,et al. Temporal changes in the causes of aortic stenosis: a surgical pathologic study of 646 cases. , 1987, Mayo Clinic proceedings.